Acinetobacter baumannii is widely distributed in nature and in hospital settings and is a
common pathogen causing various infectious diseases. Currently, the drug resistance rate …

Abstract Objectives Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our
hospital and worldwide, raising the necessity of finding effective therapies. We aimed to …

Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter
baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In …

Acinetobacter baumannii is a pathogen of increasing concern, commonly causing outbreaks
in the hospital environment. Of particular concern, A. baumannii strains exhibiting resistance …

Acinetobacter baumannii is one of the main pathogens causing nosocomial and community-
acquired infections. Tigecycline is an important antibiotic for the treatment of multidrug …

Tigecycline has an extended spectrum of in vitro antimicrobial activities, including that
against multidrug-resistant Acinetobacter. After identifying bloodstream isolates of …

What is known and objective Acinetobacter baumannii is one of the most important
nosocomial pathogens with the ability to cause infections such as meningitis, pneumonia …

Treatment of severe A. baumannii infection represents a difficult clinical challenge due to the
propensity of this organism to acquire antimicrobial resistance, resulting in the emergence of …

Acinetobacter baumannii is an important op-portunistic pathogen that is rapidly evolving
toward multidrug resistance (MDR) and is involved in various nosocomial infections …

We performed susceptibility testing using the microdilution method to determine the in-vitro
activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 …